Absci Corp. (ABSI)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$8.82+0.23%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Broken: Primary pillar broken — Reduce negative EPS from -$0.76 in 2026 to less negative in 2027: FY27 EPS -0.7% vs >-0.6% target.
Absci uses AI to speed drug discovery and protein creation. Analysts expect revenue to grow from $5.5M in 2026 to $16.5M in 2027. The company aims to fund operations into mid-2028. Recent positive news on alopecia treatment supports growth.
Absci is loss-making with negative EPS around -$0.76 in 2026 and -$0.63 in 2027. Analysts forecast a 59% revenue decline next year. The company missed earnings multiple times recently. Debt issuance may pressure the balance sheet.
The stock trades about 3% above our $11 fair value, in line with Street median. Analysts expect a 59% revenue drop next year, which seems pessimistic versus the company’s growth potential.
Breaks if: cash runway falls short of mid-2028 funding needs
Ensure sufficient cash, cash equivalents, and marketable securities to fund operations into the first half of 2028.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity, as ABSI is focused on advancing clinical programs while navigating a challenging financial landscape. The current thesis state reflects mixed signals from recent performance and management priorities.
The market appears to price in a significant expectations gap, suggesting that investors may not fully believe in the company's future potential. ABSI is currently seen as expensive compared to its peers, which could indicate that the market is cautious about its ability to deliver on growth.
Fundamentals are likely to remain under pressure due to the company's loss-making status and mixed recent performance. Management's focus on clinical development and cash management is crucial, but the elevated risk level indicates potential challenges ahead.
The most important moves since the prior daily snapshot.
Mixed, the news cuts both ways. The company advanced ABS-201 clinical development. This supports its goals for treating androgenetic alopecia and endometriosis. However, the latest earnings report missed expectations. This miss raises concerns about the company's performance.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: EPS worsens beyond -$0.76 in FY26 or fails to improve in FY27
Breaks if: revenue falls below $5.5M in FY26 or fails to grow toward $16.5M in FY27
The long-term thesis hinges on the success of ABS-201 clinical trials and the overall performance of the healthcare sector. Additionally, any cuts to guidance or worsening job reports could negatively impact sentiment and performance.
In the next 1 to 3 years, ABSI's trajectory will depend on its clinical advancements and market conditions. Not investment advice.